Acinetobacter baumannii response to cefiderocol challenge in human urine

Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore antibiotic approved to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-acquired pneumonia (HAP/VAP). Previous work determined that albumin-rich human fluids increase the minimum inhibitory con...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Brent, Escalante, Jenny, Tuttobene, Marisel R., Subils, Tomás, Mezcord, Vyanka, Pimentel, Camila, Georgeos, Nardin, Pasteran, Fernando, Rodriguez, Cecilia, Sieira, Rodrigo, Actis, Luis A., Tolmasky, Marcelo E., Bonomo, Robert A., Ramirez, María Soledad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128776/
https://www.ncbi.nlm.nih.gov/pubmed/35610334
http://dx.doi.org/10.1038/s41598-022-12829-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128776/
https://www.ncbi.nlm.nih.gov/pubmed/35610334
http://dx.doi.org/10.1038/s41598-022-12829-7

Ejemplares similares